# Cansera

Source: https://onco.cc/companies/cansera/  
OnCo record `cansera` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Cansera is a Los Angeles start-up writing software that searches images of a blood sample for the very rare cells, such as tumour cells, that can signal cancer. Its tool, CellLogic, is funded by the US National Cancer Institute.

## Summary

Cansera, Inc. describes itself as an AI-driven biotechnology start-up that unlocks digital biomarkers from routine blood tests, analysing whole fluorescent slide images of blood without preselecting what to look for, so that rare circulating cells can be found at scale rather than by manual review. In 2026 it received a National Cancer Institute STTR award to develop CellLogic, which, according to the award abstract, uses an unsupervised deep-learning model to flag candidate rare-cell regions in fluorescent whole slide images and a downstream module to characterise single cells.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: Cansera, Inc.
- HQ: Los Angeles, CA
- Type: ai-software
- Website: https://www.cansera.com/

## Notes

- Company website and the NIH RePORTER record read on 4 November 2026. Founding year not stated on the website.

## Sources

- Official website: https://www.cansera.com/
- NIH RePORTER: award 1R42CA314789-01: https://reporter.nih.gov/project-details/11409312

## Connected records

- fronts: [AI & Computation](https://onco.cc/fronts/ai-computation/), [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/)
- technologies: [Circulating tumour cell capture](https://onco.cc/technologies/ctc-capture/)

---
JSON: https://onco.cc/api/v1/entities/cansera.json